You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
先聲藥業(02096.HK)預期年度純利增長約121%至130%
格隆匯 02-21 18:54

格隆匯2月21日丨先聲藥業(02096.HK)公佈,公司預期截至2021年12月31日止年度所錄得的歸屬於公司權益股東的利潤約人民幣14.8億元至人民幣15.4億元,相比於去年同期歸屬於公司權益股東的利潤增加約人民幣8.1億元至人民幣8.7億元,增幅約121%至130%,該增長主要是由於:(i)於2020年7月上市的原研一類創新藥先必新(依達拉奉右莰醇注射用濃溶液)收入快速增長;(ii)集團通過出售SimgeneGroupLimited全部股權錄得收益,以及(iii)集團持有的投資組合的公允價值變動推高投資收益。同時,上述收益的影響部分被以下因素所抵銷:(i)2021年臨牀管線推進迅速,研發投入持續增加,以及(ii)由於加速高效推進創新藥先必新等新上市產品,營銷費用較去年同期上漲。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account